Premium
Miller Fisher syndrome following COVID ‐19 vaccines: A scoping review
Author(s) -
Kim JeeEun,
Yoon ByeolA,
Kim Yoo Hwan,
Kim Jong Kuk,
Bae Jong Seok
Publication year - 2022
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.13687
Subject(s) - vaccination , medicine , miller fisher syndrome , covid-19 , guillain barre syndrome , incidence (geometry) , immunology , pandemic , virology , disease , physics , infectious disease (medical specialty) , optics
Background and Purpose Miller Fisher syndrome (MFS), a variant of Guillain–Barré Syndrome (GBS), could be underestimated in evaluations of its adverse events (AEs) following COVID‐19 vaccination. We aimed to identify and characterize MFS following COVID‐19 vaccination. Materials and Methods Relevant studies reported on during the COVID‐19 pandemic were identified in the MEDLINE, Embase, and other databases. Results Nine cases of MFS following COVID‐19 vaccination from various regions were included. Unlike MFS following COVID‐19 infection, patients with MFS following COVID‐19 vaccination frequently presented with anti‐GQ1b antibody positivity (44%, 4/9). Unlike GBS following COVID‐19 vaccination, only two of nine (22%) cases of MFS following COVID‐19 vaccination had developed after viral‐vector‐related vaccine administration. Conclusions Miller Fisher syndrome following COVID‐19 vaccination seems to have a different pathophysiology from MFS following COVID‐19 infection and GBS following COVID‐19 vaccination. This neurological syndrome with a rare incidence and difficulty in diagnosis should be considered an AE of COVID‐19 vaccination.